Study #2024-0326
A phase Ib clinical trial to optimize risk benefit of REGN5678 (PSMAxCD28 bispecific antibody) plus Cemiplimab (anti-PD-1 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer
MD Anderson Study Status
Enrolling
Treatment Agent
REGN5678, Cemiplimab
Description
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer
Study phase:
Phase I
Physician name:
Bilal Siddiqui
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.